237 related articles for article (PubMed ID: 7824731)
1. Neoplasms in a pediatric population: 2-[F-18]-fluoro-2-deoxy-D-glucose PET studies.
Shulkin BL; Mitchell DS; Ungar DR; Prakash D; Dole MG; Castle VP; Hernandez RJ; Koeppe RA; Hutchinson RJ
Radiology; 1995 Feb; 194(2):495-500. PubMed ID: 7824731
[TBL] [Abstract][Full Text] [Related]
2. Neuroblastoma: positron emission tomography with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose compared with metaiodobenzylguanidine scintigraphy.
Shulkin BL; Hutchinson RJ; Castle VP; Yanik GA; Shapiro B; Sisson JC
Radiology; 1996 Jun; 199(3):743-50. PubMed ID: 8637999
[TBL] [Abstract][Full Text] [Related]
3. Detection of malignancies with SPECT versus PET, with 2-[fluorine-18]fluoro-2-deoxy-D-glucose.
Martin WH; Delbeke D; Patton JA; Sandler MP
Radiology; 1996 Jan; 198(1):225-31. PubMed ID: 8539384
[TBL] [Abstract][Full Text] [Related]
4. Cancer detection with whole-body PET using 2-[18F]fluoro-2-deoxy-D-glucose.
Hoh CK; Hawkins RA; Glaspy JA; Dahlbom M; Tse NY; Hoffman EJ; Schiepers C; Choi Y; Rege S; Nitzsche E
J Comput Assist Tomogr; 1993; 17(4):582-9. PubMed ID: 8331230
[TBL] [Abstract][Full Text] [Related]
5. Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT.
Newman JS; Francis IR; Kaminski MS; Wahl RL
Radiology; 1994 Jan; 190(1):111-6. PubMed ID: 8259386
[TBL] [Abstract][Full Text] [Related]
6. Triple-head SPECT with 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG): initial evaluation in oncology and comparison with FDG PET.
Macfarlane DJ; Cotton L; Ackermann RJ; Minn H; Ficaro EP; Shreve PD; Wahl RL
Radiology; 1995 Feb; 194(2):425-9. PubMed ID: 7824722
[TBL] [Abstract][Full Text] [Related]
7. Untreated lung cancer: quantification of systematic distortion of tumor size and shape on non-attenuation-corrected 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET scans.
Zasadny KR; Kison PV; Quint LE; Wahl RL
Radiology; 1996 Dec; 201(3):873-6. PubMed ID: 8939245
[TBL] [Abstract][Full Text] [Related]
8. PET FDG studies of Wilms tumors.
Shulkin BL; Chang E; Strouse PJ; Bloom DA; Hutchinson RJ
J Pediatr Hematol Oncol; 1997; 19(4):334-8. PubMed ID: 9256833
[TBL] [Abstract][Full Text] [Related]
9. Benign versus malignant intraosseous lesions: discrimination by means of PET with 2-[F-18]fluoro-2-deoxy-D-glucose.
Dehdashti F; Siegel BA; Griffeth LK; Fusselman MJ; Trask DD; McGuire AH; McGuire DJ
Radiology; 1996 Jul; 200(1):243-7. PubMed ID: 8657920
[TBL] [Abstract][Full Text] [Related]
10. Studies of primary central nervous system lymphoma with fluorine-18-fluorodeoxyglucose positron emission tomography.
Rosenfeld SS; Hoffman JM; Coleman RE; Glantz MJ; Hanson MW; Schold SC
J Nucl Med; 1992 Apr; 33(4):532-6. PubMed ID: 1552337
[TBL] [Abstract][Full Text] [Related]
11. Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma.
Gritters LS; Francis IR; Zasadny KR; Wahl RL
J Nucl Med; 1993 Sep; 34(9):1420-7. PubMed ID: 8355058
[TBL] [Abstract][Full Text] [Related]
12. Head and neck cancer: detection of recurrence with PET and 2-[F-18]fluoro-2-deoxy-D-glucose.
Lapela M; Grénman R; Kurki T; Joensuu H; Leskinen S; Lindholm P; Haaparanta M; Ruotsalainen U; Minn H
Radiology; 1995 Oct; 197(1):205-11. PubMed ID: 7568825
[TBL] [Abstract][Full Text] [Related]
13. Pheochromocytomas: imaging with 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET.
Shulkin BL; Thompson NW; Shapiro B; Francis IR; Sisson JC
Radiology; 1999 Jul; 212(1):35-41. PubMed ID: 10405717
[TBL] [Abstract][Full Text] [Related]
14. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose.
Wahl RL; Cody RL; Hutchins GD; Mudgett EE
Radiology; 1991 Jun; 179(3):765-70. PubMed ID: 2027989
[TBL] [Abstract][Full Text] [Related]
15. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays.
Dehdashti F; Mortimer JE; Siegel BA; Griffeth LK; Bonasera TJ; Fusselman MJ; Detert DD; Cutler PD; Katzenellenbogen JA; Welch MJ
J Nucl Med; 1995 Oct; 36(10):1766-74. PubMed ID: 7562040
[TBL] [Abstract][Full Text] [Related]
16. [Cancer screening with whole-body FDG PET].
Yasuda S; Ide M; Takagi S; Shohtsu A
Kaku Igaku; 1996 Oct; 33(10):1065-71. PubMed ID: 8952258
[TBL] [Abstract][Full Text] [Related]
17. Pediatric FDG PET/CT: Physiologic uptake, normal variants, and benign conditions [corrected].
Bestic JM; Peterson JJ; Bancroft LW
Radiographics; 2009; 29(5):1487-500. PubMed ID: 19755607
[TBL] [Abstract][Full Text] [Related]
18. Positron emission tomography/computed tomography with 18fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma.
Arush MW; Israel O; Postovsky S; Militianu D; Meller I; Zaidman I; Sapir AE; Bar-Shalom R
Pediatr Blood Cancer; 2007 Dec; 49(7):901-5. PubMed ID: 17252575
[TBL] [Abstract][Full Text] [Related]
19. Lung cancer: reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-D-glucose uptake at PET.
Minn H; Zasadny KR; Quint LE; Wahl RL
Radiology; 1995 Jul; 196(1):167-73. PubMed ID: 7784562
[TBL] [Abstract][Full Text] [Related]
20. Assessment of primary and metastatic ovarian cancer by positron emission tomography (PET) using 2-[18F]deoxyglucose (2-[18F]FDG).
Hubner KF; McDonald TW; Niethammer JG; Smith GT; Gould HR; Buonocore E
Gynecol Oncol; 1993 Nov; 51(2):197-204. PubMed ID: 8276294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
